^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Model Information

     Data Set                     WORK.DBRW_DATA           
     Dependent Variable           CHG                      
     Covariance Structure         Unstructured             
     Subject Effect               id                       
     Estimation Method            REML                     
     Residual Variance Method     None                     
     Fixed Effects SE Method      Kenward-Roger            
     Degrees of Freedom Method    Kenward-Roger            


 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SE, LS Mean Diff, 95% CI and p-value ha
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                    Class Level Information
 
      Class      Levels    Values

      id             35    10631001 10631002 10631003    
                           11601006 11601007 13031001    
                           13031004 13581001 13581014    
                           13991002 13991004 13991007    
                           13991009 13991010 16591001    
                           16591003 16591006 17601002    
                           17601003 17601005 17601007    
                           17601012 17601014 17601025    
                           17661002 17661004 17661006    
                           19691001 19731001 19731002    
                           19731006 19831001 19831005    
                           19831008 19901003             
      AVISITN         2    4 12                          
      trtn            3    1 2 3                         
      SSNRISN         2    1 2                           
      wk12            2    0 1                           
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SE, LS Mean Diff, 95% CI and p-value ha
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                          Dimensions

              Covariance Parameters             3
              Columns in X                     39
              Columns in Z                      0
              Subjects                         35
              Max Obs per Subject               2


                    Number of Observations

          Number of Observations Read              60
          Number of Observations Used              60
          Number of Observations Not Used           0


 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SE, LS Mean Diff, 95% CI and p-value ha
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Iteration History
 
  Iteration    Evaluations    -2 Res Log Like       Criterion

          0              1       387.85404278                
          1              2       382.01149827      0.00012212
          2              1       381.99237716      0.00000090
          3              1       381.99224324      0.00000000


                   Convergence criteria met.                    


                Covariance Parameter Estimates
 
                Cov Parm    Subject    Estimate

                UN(1,1)     id           152.20
                UN(2,1)     id          76.7514
                UN(2,2)     id           126.07
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SE, LS Mean Diff, 95% CI and p-value ha
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                        Fit Statistics

             -2 Res Log Likelihood           382.0
             AIC (Smaller is Better)         388.0
             AICC (Smaller is Better)        388.6
             BIC (Smaller is Better)         392.7


                Null Model Likelihood Ratio Test
 
                  DF    Chi-Square      Pr > ChiSq

                   2          5.86          0.0533


 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SE, LS Mean Diff, 95% CI and p-value ha
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                 Type 3 Tests of Fixed Effects
 
                           Num     Den
     Effect                 DF      DF    F Value    Pr > F

     BASE                    1    29.3      10.82    0.0026
     trtn                    2    26.1       0.02    0.9786
     wk12                    1    20.3       2.67    0.1178
     SSNRISN                 1    26.3       0.00    0.9838
     BASE*wk12               1    20.5       1.50    0.2353
     trtn*SSNRISN            2    26.8       0.18    0.8404
     trtn*wk12               2    19.6       0.08    0.9206
     SSNRISN*wk12            1    19.7       1.13    0.3002
     trtn*SSNRISN*wk12       2    19.6       0.37    0.6975


 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SE, LS Mean Diff, 95% CI and p-value ha
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                      Least Squares Means
 
                       Concomitant
                       Use of
                       SSRI/SNRI                Standard
 Effect         trtn   (N)           Estimate      Error     DF

 trtn*SSNRISN   1      1             -15.8049     8.4605   29.5
 trtn*SSNRISN   1      2             -20.2144     4.1464   24.4
 trtn*SSNRISN   2      1             -20.7640     7.4472   22.1
 trtn*SSNRISN   2      2             -17.7780     3.1848   26.2
 trtn*SSNRISN   3      1             -19.3733     8.1472   28.3
 trtn*SSNRISN   3      2             -17.6406     3.4632   23.6

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SE, LS Mean Diff, 95% CI and p-value ha
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                      Least Squares Means
 
                      Concomitant
                      Use of
                      SSRI/SNRI
Effect         trtn   (N)           t Value   Pr > |t|    Alpha

trtn*SSNRISN   1      1               -1.87     0.0717     0.05
trtn*SSNRISN   1      2               -4.88     <.0001     0.05
trtn*SSNRISN   2      1               -2.79     0.0107     0.05
trtn*SSNRISN   2      2               -5.58     <.0001     0.05
trtn*SSNRISN   3      1               -2.38     0.0244     0.05
trtn*SSNRISN   3      2               -5.09     <.0001     0.05

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SE, LS Mean Diff, 95% CI and p-value ha
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                      Least Squares Means
 
                          Concomitant
                          Use of
                          SSRI/SNRI
    Effect         trtn   (N)              Lower       Upper

    trtn*SSNRISN   1      1             -33.0968      1.4870
    trtn*SSNRISN   1      2             -28.7649    -11.6640
    trtn*SSNRISN   2      1             -36.2061     -5.3218
    trtn*SSNRISN   2      2             -24.3222    -11.2338
    trtn*SSNRISN   3      1             -36.0539     -2.6926
    trtn*SSNRISN   3      2             -24.7950    -10.4862
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SE, LS Mean Diff, 95% CI and p-value ha
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Model Information

     Data Set                     WORK.DBRW_DATA           
     Dependent Variable           CHG                      
     Covariance Structure         Unstructured             
     Subject Effect               id                       
     Estimation Method            REML                     
     Residual Variance Method     None                     
     Fixed Effects SE Method      Kenward-Roger            
     Degrees of Freedom Method    Kenward-Roger            


 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SE, LS Mean Diff, 95% CI and p-value ha
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                    Class Level Information
 
      Class      Levels    Values

      id             21    10631001 10631002 10631003    
                           11601006 11601007 13031001    
                           13581001 13581014 13991002    
                           13991004 13991007 13991009    
                           16591001 17601005 17601007    
                           17601014 17661004 19731002    
                           19731006 19831001 19901003    
      AVISITN         2    4 12                          


                          Dimensions

              Covariance Parameters             3
              Columns in X                     10
              Columns in Z                      0
              Subjects                         21
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SE, LS Mean Diff, 95% CI and p-value ha
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                          Dimensions

              Max Obs per Subject               2


                    Number of Observations

          Number of Observations Read              37
          Number of Observations Used              37
          Number of Observations Not Used           0


                       Iteration History
 
  Iteration    Evaluations    -2 Res Log Like       Criterion

          0              1       236.16547530                
          1              2       231.28126157      0.00000180
          2              1       231.28109732      0.00000000
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SE, LS Mean Diff, 95% CI and p-value ha
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                   Convergence criteria met.                    


                Covariance Parameter Estimates
 
                Cov Parm    Subject    Estimate

                UN(1,1)     id           163.12
                UN(2,1)     id          92.8977
                UN(2,2)     id           144.53


                        Fit Statistics

             -2 Res Log Likelihood           231.3
             AIC (Smaller is Better)         237.3
             AICC (Smaller is Better)        238.3
             BIC (Smaller is Better)         240.4
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SE, LS Mean Diff, 95% CI and p-value ha
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                Null Model Likelihood Ratio Test
 
                  DF    Chi-Square      Pr > ChiSq

                   2          4.88          0.0870


                 Type 3 Tests of Fixed Effects
 
                            Num     Den
    Effect                   DF      DF    F Value    Pr > F

    BASE                      1      16       5.07    0.0387
    trtn1                     1      16       0.08    0.7776
    wk12                      1    12.6       0.56    0.4662
    SSNRISN1                  1      16       0.28    0.6058
    BASE*wk12                 1    12.6       0.15    0.7065
    trtn1*SSNRISN1            1      16       0.30    0.5889
    trtn1*wk12                1    12.2       0.01    0.9436
    wk12*SSNRISN1             1    12.5       0.34    0.5714
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SE, LS Mean Diff, 95% CI and p-value ha
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                 Type 3 Tests of Fixed Effects
 
                            Num     Den
    Effect                   DF      DF    F Value    Pr > F

    trtn1*wk12*SSNRISN1       1    12.6       0.07    0.8029


                           Estimates
 
                              Standard
Label               Estimate     Error    DF  t Value  Pr > |t|

1 ACT-PBO  Week 4     6.2650   12.9116    16     0.49    0.6341
2 ACT-PBO  Week 4    -1.9313    6.7245    16    -0.29    0.7776
1 ACT-PBO  Week 12    0.8213   17.3130  13.5     0.05    0.9629
2 ACT-PBO  Week 12   -2.4353    7.4204  12.9    -0.33    0.7481

 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SE, LS Mean Diff, 95% CI and p-value ha
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                           Estimates
 
       Label                Alpha       Lower       Upper

       1 ACT-PBO  Week 4     0.05    -21.1062     33.6363
       2 ACT-PBO  Week 4     0.05    -16.1866     12.3240
       1 ACT-PBO  Week 12    0.05    -36.4302     38.0727
       2 ACT-PBO  Week 12    0.05    -18.4847     13.6141


                           Contrasts
 
                                           Num    Den
 Label                                      DF     DF   F Value

 Treatment*Week 4*Subgroup Interaction       1     16      0.30
 Treatment*Week 12*Subgroup Interaction      1   13.5      0.03

 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SE, LS Mean Diff, 95% CI and p-value ha
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                           Contrasts
 
        Label                                    Pr > F

        Treatment*Week 4*Subgroup Interaction    0.5889
        Treatment*Week 12*Subgroup Interaction   0.8740
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SE, LS Mean Diff, 95% CI and p-value ha
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Model Information

     Data Set                     WORK.DBRW_DATA           
     Dependent Variable           CHG                      
     Covariance Structure         Unstructured             
     Subject Effect               id                       
     Estimation Method            REML                     
     Residual Variance Method     None                     
     Fixed Effects SE Method      Kenward-Roger            
     Degrees of Freedom Method    Kenward-Roger            


 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SE, LS Mean Diff, 95% CI and p-value ha
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                    Class Level Information
 
      Class      Levels    Values

      id             26    10631001 10631003 11601006    
                           13031001 13031004 13581001    
                           13581014 13991010 16591003    
                           16591006 17601002 17601003    
                           17601007 17601012 17601025    
                           17661002 17661004 17661006    
                           19691001 19731001 19731002    
                           19731006 19831001 19831005    
                           19831008 19901003             
      AVISITN         2    4 12                          


                          Dimensions

              Covariance Parameters             3
              Columns in X                     10
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SE, LS Mean Diff, 95% CI and p-value ha
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                          Dimensions

              Columns in Z                      0
              Subjects                         26
              Max Obs per Subject               2


                    Number of Observations

          Number of Observations Read              44
          Number of Observations Used              44
          Number of Observations Not Used           0


                       Iteration History
 
  Iteration    Evaluations    -2 Res Log Like       Criterion

          0              1       290.97381163                
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SE, LS Mean Diff, 95% CI and p-value ha
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Iteration History
 
  Iteration    Evaluations    -2 Res Log Like       Criterion

          1              2       282.23182628      0.00036968
          2              1       282.18762104      0.00000824
          3              1       282.18670187      0.00000000


                   Convergence criteria met.                    


                Covariance Parameter Estimates
 
                Cov Parm    Subject    Estimate

                UN(1,1)     id           163.41
                UN(2,1)     id           105.53
                UN(2,2)     id           130.78
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SE, LS Mean Diff, 95% CI and p-value ha
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                        Fit Statistics

             -2 Res Log Likelihood           282.2
             AIC (Smaller is Better)         288.2
             AICC (Smaller is Better)        289.0
             BIC (Smaller is Better)         292.0


                Null Model Likelihood Ratio Test
 
                  DF    Chi-Square      Pr > ChiSq

                   2          8.79          0.0124


 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SE, LS Mean Diff, 95% CI and p-value ha
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                 Type 3 Tests of Fixed Effects
 
                            Num     Den
    Effect                   DF      DF    F Value    Pr > F

    BASE                      1    19.3       8.13    0.0101
    trtn2                     1    19.7       0.24    0.6266
    wk12                      1    14.3       1.51    0.2382
    SSNRISN1                  1    19.2       0.32    0.5779
    BASE*wk12                 1    14.4       0.61    0.4482
    trtn2*SSNRISN1            1    19.3       0.07    0.7908
    trtn2*wk12                1    14.3       1.72    0.2104
    wk12*SSNRISN1             1      14       0.47    0.5063
    trtn2*wk12*SSNRISN1       1    13.8       0.31    0.5892


 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SE, LS Mean Diff, 95% CI and p-value ha
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                           Estimates
 
                               Standard
Label                Estimate     Error    DF  t Value  Pr > |t|

1 ACT-PBO    Week 4   -0.9754   12.9268  19.2    -0.08    0.9406
2 ACT-PBO  Week 4      2.7810    5.6264  19.7     0.49    0.6266
1 ACT-PBO  Week 12    -0.7059   12.9955  17.8    -0.05    0.9573
2 ACT-PBO  Week 12    -3.5038    5.5097  17.6    -0.64    0.5330

                           Estimates
 
      Label                 Alpha       Lower       Upper

      1 ACT-PBO    Week 4    0.05    -28.0120     26.0613
      2 ACT-PBO  Week 4      0.05     -8.9676     14.5297
      1 ACT-PBO  Week 12     0.05    -28.0282     26.6163
      2 ACT-PBO  Week 12     0.05    -15.1000      8.0924
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SE, LS Mean Diff, 95% CI and p-value ha
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                           Contrasts
 
                                           Num    Den
 Label                                      DF     DF   F Value

 Treatment*Week 4*Subgroup Interaction       1   19.3      0.07
 Treatment*Week 12*Subgroup Interaction      1   17.8      0.04

                           Contrasts
 
        Label                                    Pr > F

        Treatment*Week 4*Subgroup Interaction    0.7908
        Treatment*Week 12*Subgroup Interaction   0.8439
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SE, LS Mean Diff, 95% CI and p-value ha
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
